顺铂培美曲塞重组人血管内皮抑制素注射液联合治疗晚期肺腺癌效果评价.docVIP

顺铂培美曲塞重组人血管内皮抑制素注射液联合治疗晚期肺腺癌效果评价 　　[摘要]目的 探?顺铂、培美曲塞、重组人血管内皮抑制素注射液联合治疗晚期肺腺癌的效果。方法 选取2013年6月～2016年6月我院收治的62例晚期肺腺癌患者作为研究对象，对其临床相关资料进行分析，将采用顺铂和培美曲塞进行治疗的30例患者作为对照组，将采用顺铂、培美曲塞及重组人血管内皮抑制素注射液进行治疗的32例患者作为观察组。比较两组患者的治疗效果和不良反应情况。结果 观察组患者的疾病控制率（87.50%）高于对照组（63.33%），差异有统计学意义（P0.05）。两组患者的不良反应发生率比较，差异无统计学意义（P0.05）。结论 将顺铂、培美曲塞及重组人血管内皮抑制素注射液联合应用于晚期肺腺癌患者的治疗中，可以将肿瘤的中位进展时间明显延长，且不会增加患者的不良反应，是一种有效的治疗方案，值得临床推广应用。 　　[关键词]顺铂；培美曲塞；重组人血管内皮抑制素注射液；晚期肺腺癌；生活质量 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721（2017）11（a）-0152-03 　　Effect evaluation of Cisplatin，Pemetrexed and Recombinant Human Endostatin Injection in the treatment of advanced lung adenocarcinoma 　　CONG Yun-yan LYU Wei-ze LIN Zhong 　　Department of Tumor Chemotherapy，the Fifth Hospital Affiliated to Zhongshan University，Guangdong Province，Zhuhai 519000，China 　　[Abstract]Objective To investigate the effects of Cisplatin and Pemetrexed，Recombinant Human Endostatin Injection combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods From June 2013 to June 2016，62 patients with advanced lung adenocarcinoma treated in our hospital were selected as objects，and the clinical data was analyzed.30 patients who treated with Cisplatin and Pemetrexed was the control group，32 patients who treated with Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection was the observation group.The treatment effects and adverse reactions were compared between the two groups.Results The disease control rate in the observation group （87.50%） was higher than that in the control group （63.33%），and the difference was statistically significant （P0.05）.The adverse reaction rate were compared between the two groups，and the difference was not statistically significant （P0.05）.Conclusion The treatment of Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection combined application in advanced lung adenocarcinoma，the median time to progression of the tumor was significantly prolonged，and will not increase the adverse rea